Insmed, Inc. (NASDAQ:INSM) Probability Sentiment SUMMARY Pulmonary arterial hypertension (PAH) comprises a group of severe [...]
Humacyte, Inc. (NASDAQ:HUMA) Probability Sentiment SUMMARY Regenerative medicine, the therapeutic research devoted to the regrowth [...]
Bioatla, Inc. (NASDAQ:BCAB) Probability Sentiment SUMMARY Finding the right combination cancer immunotherapy using PD-1, PDL-1 [...]
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Probability Sentiment SUMMARY While current anti-depressants provide some relief, most physicians [...]
Albireo Pharma, Inc. (NASDAQ:ALBO) Probability Sentiment SUMMARY Alagille syndrome (ALGS) is a rare, life-threatening genetic [...]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Probability Sentiment SUMMARY Apellis Pharmaceuticals is advancing a portfolio of drugs [...]
Glaukos subsequently advanced a second-generation treatment, Epioxa, through phase III trials. SanaCurrents assigns a pivolat probability Glaukos will submit an NDA for Epioxa in 2022.
UK-based Amryt Pharma plc (NASDAQ:AMYT) said before the market opened on February 28 it had received a complete response letter [...]